On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) or Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as maintenance therapy for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]
Small cell lung cancer (SCLC) can be a highly aggressive form of lung cancer and can be difficult to treat. It is the rarest of the major lung cancer types and represents just 15% of all diagnoses. Unfortunately, few [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, [...]
Author: Carl M. Gay, MD, PhD of MD Anderson Cancer Center Dr. Carl Gay received our 2018 Young Investigator Award. He graciously agreed to write this summary of new research, including his own, that is poised to make a [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung Cancer 1. What is Small Cell Lung Cancer? Small cell lung cancer (SCLC) is a type of lung cancer named for the very small, oval shaped cancer cells [...]